Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who Will Run FDA Under Obama?

This article was originally published in The Pink Sheet Daily

Executive Summary

Steve Nissen has been getting the most attention, but there are plenty of other possibilities. Here are some of the names we’ve heard.

You may also be interested in...



FDA’s Von Eschenbach Returns To Texas In January; Will He Also Return To MD Anderson?

Von Eschenbach’s resignation is effective Jan. 20; FDA commissioner expresses hope that senior team will remain at least partly intact.

FDA’s Von Eschenbach Returns To Texas In January; Will He Also Return To MD Anderson?

Von Eschenbach’s resignation is effective Jan. 20; FDA commissioner expresses hope that senior team will remain at least partly intact.

Who Should Be The Next FDA Commissioner? David Kessler Weighs In

Former FDA Commissioner David Kessler has a few ideas about the kind of person President-elect Barack Obama should pick to succeed Andrew von Eschenbach at FDA after he takes office Jan. 20

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067086

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel